Targeting GNAQ/11 through PKC inhibition in uveal melanoma.

Abstract excerpt

Uveal melanoma is a rare malignancy affecting 5.1 patients/million per year with definitive treatment options of enucleation or radiation therapy to the primary tumor. Unfortunately, no FDA-approved systemic therapies exist for patients in the adjuvant or metastatic setting. Molecular profiling over the past decade has helped define uveal melanomas by characteristic mutations: GNAQ, GNA11, BAP1, SF3B1, and EIF1AX...

Topics

Join the communities discussing this publication.

• GTP-Binding Protein alpha Subunits
• GTP-Binding Protein alpha Subunits, Gq-G11
• Melanoma
• Mutation
• Uveal Melanoma